.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Queensland Health
Citi
Chubb
Cerilliant
Johnson and Johnson
Boehringer Ingelheim
McKinsey
Fuji
UBS

Generated: December 13, 2017

DrugPatentWatch Database Preview

MORPHABOND ER Drug Profile

« Back to Dashboard

When do Morphabond Er patents expire, and when can generic versions of Morphabond Er launch?

Morphabond Er is a drug marketed by Daiichi Sankyo Inc and is included in one NDA. There is one patent protecting this drug.

This drug has nineteen patent family members in eight countries.

The generic ingredient in MORPHABOND ER is morphine sulfate. There are twenty-three drug master file entries for this compound. Fifty-three suppliers are listed for this compound. Additional details are available on the morphine sulfate profile page.
Drug patent expirations by year for MORPHABOND ER

Pharmacology for MORPHABOND ER

Drug ClassOpioid Agonist
Mechanism of ActionFull Opioid Agonists

Medical Subject Heading (MeSH) Categories for MORPHABOND ER

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Daiichi Sankyo IncMORPHABOND ERmorphine sulfateTABLET, EXTENDED RELEASE;ORAL206544-001Oct 2, 2015RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Daiichi Sankyo IncMORPHABOND ERmorphine sulfateTABLET, EXTENDED RELEASE;ORAL206544-004Oct 2, 2015RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Daiichi Sankyo IncMORPHABOND ERmorphine sulfateTABLET, EXTENDED RELEASE;ORAL206544-002Oct 2, 2015RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Daiichi Sankyo IncMORPHABOND ERmorphine sulfateTABLET, EXTENDED RELEASE;ORAL206544-004Oct 2, 2015RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Daiichi Sankyo IncMORPHABOND ERmorphine sulfateTABLET, EXTENDED RELEASE;ORAL206544-001Oct 2, 2015RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Daiichi Sankyo IncMORPHABOND ERmorphine sulfateTABLET, EXTENDED RELEASE;ORAL206544-002Oct 2, 2015RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Daiichi Sankyo IncMORPHABOND ERmorphine sulfateTABLET, EXTENDED RELEASE;ORAL206544-003Oct 2, 2015RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Daiichi Sankyo IncMORPHABOND ERmorphine sulfateTABLET, EXTENDED RELEASE;ORAL206544-003Oct 2, 2015RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: MORPHABOND ER

Country Document Number Estimated Expiration
Japan2016138126► Subscribe
Canada2696341► Subscribe
Australia2017200414► Subscribe
China101801350► Subscribe
China105534936► Subscribe
Mexico2010001812► Subscribe
BrazilPI0815387► Subscribe
World Intellectual Property Organization (WIPO)2010019279► Subscribe
Canada2734075► Subscribe
European Patent Office2331080► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
Julphar
McKinsey
US Army
Cipla
Colorcon
Chinese Patent Office
QuintilesIMS
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot